Granulocyte Colony Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells: An Alternative Cellular Source...

Area of Science:

• Immunology
• Cell Therapy
• Hematology

Background:

• Granulocyte colony-stimulating factor (G-CSF) is used for stem cell transplants but is typically avoided for CAR-T production due to perceived negative effects on lymphocytes.
• The increasing demand for CAR-T and NK-CAR therapies necessitates exploring alternative cell sources.
• Peripheral blood stem cell (PBSC) products mobilized with G-CSF are a potential, underutilized source for cell therapies.

Purpose of the Study:

• To review recent experimental evidence on the function and suitability of T and NK lymphocytes collected after G-CSF mobilization for CAR-T generation.
• To evaluate if G-CSF-mobilized PBSC products can be a viable source for adoptive cell therapies.

Main Methods:

• Systematic review of recent literature focusing on experimental verification of T and NK lymphocyte function post-G-CSF mobilization.
• Analysis of studies examining CAR-T generation from G-CSF-mobilized apheresis products.
• Assessment of lymphocyte phenotype, sub-populations, proliferation, cytokine secretion, and cytotoxic activity.

Main Results:

• T-cell phenotype, including CD4+/CD8+ ratios and sub-population stability, remains largely unchanged after G-CSF mobilization.
• Lymphocyte expansion, proliferation rates, pro-inflammatory cytokine secretion, and cytotoxic functions are not significantly affected by G-CSF mobilization.
• CAR-T cells can be successfully generated from G-CSF-mobilized apheresis products.

Conclusions:

• G-CSF-mobilized T cells are a suitable and potentially valuable source for adoptive cell therapies, including CAR-T production.
• Utilizing G-CSF-mobilized PBSC products can help meet the high demand for CAR therapies and leverage existing cryopreserved collections.
• This approach offers a promising strategy to increase the availability and accessibility of CAR-T therapies.